Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
Optimi Health Completes Expansion Of On-Site Analytical Laboratory
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.
Red Light Holland Files International Patent Application for 'Find Your Dose' Customization of Microdosing Kits Based on Biometric and Movement Data
Red Light Holland submits a new patent application for its microdosing kits.
New York Lawmakers Discuss Competing Psychedelics Reform Bills Ahead Of Key Deadline
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
Wesana announces a strategic review of its assets and a decision to focus on drug development.
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
Pharmather announces receiving a patent from the USPTO for its "ketamine flow synthesis". Pharmather has exclusive worldwide development and commercial rights to this IP.
Ketamine Wellness Centers (KWC) Introduces NAD+ Infusion Therapy
Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.
